Merck and moderna initiate phase 3 study evaluating v940 (mrna-4157) in combination with keytruda® (pembrolizumab) for adjuvant treatment of patients with resected high-risk (stage iib-iv) melanoma

Rahway, n.j. & cambridge, mass.--(business wire)---- $mrk #mrk--merck (nyse: mrk), known as msd outside of the united states and canada, and moderna, inc. (nasdaq: mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced the initiation of the pivotal phase 3 randomized v940-001 clinical trial evaluating v940 (mrna-4157), an investigational individualized neoantigen therapy (int), in combination with keytruda, merck's anti-pd-1 therapy, as an adjuvant treatment.
MRNA Ratings Summary
MRNA Quant Ranking